Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright
February 12, 2025 6:44 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $81.00 (from $87.00) while maintaining a Buy rating.
The analyst comments "VERITAC-2 trial design differences can impact mPFS outcome. As Arvinas plans to share the Phase 3 data from the vepdeg monotherapy trial in 1Q 2025, we remain encouraged that a CBR of 37.1% and 38.9% in 200 mg QD and 500 mg QD is impressive, and we consider it might result in a competitive mPFS in comparison to the EMERALD data of 3.8 months (elacestrant arm) versus 1.9 months (control).... More
